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Abstract. The addition of polysorbate 20 (T20) is required to achieve “sink” conditions during a dissolu-
tion test for tablets with candesartan cilexetil (CC). Polysorbate 20 (0.35%–0.7%w/w) added to 0.05 mol/L
of phosphate buffer pH 6.5 dramatically increased the apparent solubility of the drug from 0.8 μg/ml even to
353 μg/ml, while its effect in lower pH or in water was much smaller (20 μg/ml in pH 4.5). The increased
concentration of phosphate salts (0.2 mol/l) at pH 6.5 in the presence of 0.7% of polysorbate 20, resulted in
further increase of candesartan cilexetil solubility to 620 μg/ml. The change of pH from 1.2 to 7.4 resulted in a
1.5-fold increase of the activation energy and, depending on temperature, 8–14-fold decrease of the degra-
dation rate. When polysorbate 20 increased the activation energy 2-fold, independent of pH, it protected
candesartan cilexetil from degradation; however, this effect was temperature dependent andwas very small at
310 K—the degradation rate in pH 6.5 decreased by 13% only. It was calculated that in the phosphate buffer
pH 6.5 with polysorbate, one can expect during 24 h the degradation at the level of 9.3%, thus a flow-through
dissolution apparatus was recommended for testing prolonged release dosage forms.
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INTRODUCTION
Dissolution testing has been employed as a quality con-
trol procedure in pharmaceutical production, and the objec-
tives of dissolution testing vary during the life cycle of a
dosage form. In product development, it is used to assist in
the selection of a candidate formulation, in research to detect
the influence of critical manufacturing variables, such as the
binder effect, mixing effect, granulation procedure, coating
parameters, and excipient type [1]. It, therefore, becomes
apparent that the dissolution data derived from the physico-
chemically and hydro-dynamically defined conditions is re-
quired in order to compare various in vitro dissolution data
and to be able to use such results as a surrogate for possible
in vivo bioequivalence testing and in vitro-in vivo correlations
(IVIVC) [1, 2].
Dissolution characteristics of oral formulations should be
evaluated using the test media within the physiological pH
range of 1.2–6.8 (1.2–7.5 for modified-release formulations).
Selection of the dissolution medium is based, in part, on the
solubility data and its stability measured at the pre-formula-
tion stage [2]. In order to ensure that the dissolution test is
measuring the properties of drug release without the limita-
tions imposed by the experimental conditions, the medium is
selected to ensure that the concentration gradient remains
large and “sink” conditions occur for the duration of the test.
“Sink” conditions are achieved when the drug solubility is 10
times the total concentration of the drug in a vessel or at least
greater than three times [2, 3].
Candesartan cilexetil (CC), whose chemical structure is
presented in Fig. 1, is a potent and long-acting angiotensin II
receptor blocker, commonly used to treat hypertension in
monotherapy or in combination with other antihypertensive
agents, such as diuretics. CC is available as nonmodified re-
lease tablets in doses of 8, 16, or 32 mg (an original product
from Astra Zeneca and generics from e.g., Sandoz, Krka,
Zentiva). CC is a pro-drug, which is rapidly and completely
converted into an active moiety, candesartan, during a
gastrointestinal absorption [4]. Miyabashi [5] has identified
candesartan and desethyl candesartan, as a metabolite of
CC, in plasma samples.
CC is practically insoluble in water (<0.05 μg/mL) and is a
highly lipophilic compound. The partition coefficient (Coctanol/
Cwater) at pHs 1.1, 6.9, and 8.9 is >1,000, indicating high
hydrophobicity [4, 6]. Solubility of CC in a simulated
gastric fluid and intestinal fluid has been reported as 0.6
and 8.6 μg/mL, respectively [7]. Low solubility of CC across
the physiological pH range resulted in an incomplete absorption
from the gastrointestinal tract and, hence, it is reported to have
an oral bioavailability of about 15% [4, 8]. Based on CC’s
solubility across the physiological pH and absorption character-
istics, it is classified in the Biopharmaceutics Classification
System as a class II drug [8].
Solubility of CC in various surfactant solutions and oils
has been reported. It is slightly soluble in Miglyol 812 or
Labrafac and sparingly soluble in Labrafil. Polysorbate 80,
macrogol 400, Cremophor, Labrasol, and Transcutol P were
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used to solubilize CC in water in order to develop a self-
microemulsifying formulation as a new dosage form [8]. In a
phosphate buffer (PBS) pH 6.5 containing 0.7% of polysor-
bate 20 (T20) and in PBS pH 6.8 with 1% of sodium lauryl
sulfate, the solubilities have been reported as 125.0 μg/mL [9]
and 1.0 μg/ml [10], respectively. This indicates how important
a choice of additives in dissolution media is when “sink”
conditions have to be achieved.
In its solid state, CC is stable against temperature, moisture,
and light but undergoes degradation when subjected to acidic,
basic, aqueous hydrolysis, and oxidative conditions [4, 11]. Rao
et al. [12] have determined and identified several impurities of CC
in alkaline or acidic conditions and under oxidative and hydrolytic
stress. CC is highly sensitive to bases and is degraded to
candesartan and transesterification products (methylcandesartan,
ethylcandesartan, hydroxyethylcandesartan) [11, 12]. Mohan et al.
[13] determined and identified five degradation products of CC in
tablets. Subjected to 40°C and 75%RH, the parent drug molecule
underwent reactions which resulted in the formation of
desethylcandesartan cilexetil and ethylcandesartan cilexetil as main
impurities.
Poor solubility and stability of the drug require special
conditions when dosage forms are subjected to dissolution
tests and dissolution medium should be carefully chosen.
From the collected data, a summary of the CC dissolution
media recommended in literature was made (Table I). For
the purpose of the in vitro release study from CC dosage forms
(tablets, nanoemulsions, nanosuspensions, polymeric micelles,
self-microemulsifying drug delivery systems (SMEDDS)), dis-
solution media in the pH range from 1.0 to 7.2 were selected.
Considering the solubility and stability of CC, a dissolution
media such as the phosphate buffers pH 7.2, pH 6.8 (with
0.1% T20), and pH 6.5 (with 0.02% T20) were recommended.
Despite the indicated poor solubility [6] and susceptibility to
hydrolysis into desethylcandesartan [11] in the acidic medium,
dissolution tests were carried out in the acetate buffer pH 4.5,
0.1 mol/L HCl and simulated gastric fluid at pH 1.2.
The aims of the present study were to investigate the
solubility of CC in the selected dissolution media and to
indicate the kinetics of CC degradation in the aqueous solu-
tion as a function of pH, temperature, surfactant concentra-
tion, and buffer type at different pHs (1.2–7.4). The obtained
data should be helpful in selecting an appropriate acceptor
fluid for dissolution testing.
MATERIALS AND METHODS
Chemicals
Candesartan cilexetil (CC) was kindly donated by Polpharma
S.A. Pharmaceutical Works (Starogard, Poland). Acetonitrile
(Merck, Darmstadt, Germany) and methanol (POCh, Gliwice,
Poland) were of HPLC grade. Sodium hydroxide, dipotassium
phosphate, and phosphoric acid were purchased from POCh as
reagents for preparation of buffered solutions. High-purity water
was prepared by use of aMilliporeElix 3 (Millipore, Bedford,MA,
USA) water purification system. Phosphate-buffered saline (PBS
0.05mol/L) pH4.5, pH 6.5, and pH7.4were prepared by dissolving
potassium dihydrogen phosphate in water and adjusting it to a
desired pH with 0.1 mol/L of sodium hydroxide. In the same way,
PBS pH 6.5 at concentrations of 0.01 and 0.2 mol/L was prepared.
The pH was measured at room temperature (pH-meter
(type 350), Orion Research, Boston, USA). Ionic
strengths were 0.05, 0.079, and 0.123 mol/L for pH 4.5,
pH 6.5, and pH 7.4 buffer solutions (0.05 mol/L), respectively.
Hydrochloric acid (HCl; POCh, Gliwice, Poland) was used in
the concentration of 0.1 mol/L (the measured pH was 1.2).
Polysorbate 20 (T20, Tween 20) was purchased from
Sigma Aldrich (Steinheim, Germany). Solutions containing
either 0.35% or 0.7% (w/w) of T20 were prepared by
dissolving the surfactant in 0.1 mol/L HCl or 0.05 mol/L PBS
pHs 4.5 and 6.5.
HPLC Analysis
Chromatographic separation and quantitative analysis were
performed using HPLC apparatus (Merck-Hitachi, Darmstadt,
Germany) equipped with C18 column (5 μm LiChrosphere 250×
4 mm, Merck) and UV–Vis detector at 215 nm. A mixture of
0.05 mol/L of phosphate buffer pH 3.0:acetonitrile:methanol
(30:50:20 v/v) was used as a mobile phase. Prior to injection, the
samples were diluted with methanol.
HPLC Validation
The method was validated for the limit of quantification
(LOQ) and limit of detection (LOD), linearity, accuracy, and pre-
cision.A stock solution ofCC (1mg/ml) was prepared inmethanol,
and further dilution was also made in the same solvent.
Linearity
The linearity of the method was checked by analyzing six
solutions of CC in the concentration range of 0.2–
10.0 μg/mL and prepared in triplicate. The least-squares linear
regression analysis of the peak area and concentration data was
performed.
Fig. 1. Chemical structure of candesartan cilexetil (1RS)-1-
[[(Cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-
yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate
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Limits of detection (LOD) and quantification (LOQ)
The LOQ and LOD of the method were determined,
based on signal-to-noise ratios. LOD was determined as the
lowest CC concentration which can be detected by the HPLC
system producing a signal-to-noise ratio of about 3. LOQ was
the concentration producing a signal-to-noise ratio of 10.
Accuracy and precision
The intra-day and inter-day accuracy and precision were
established using samples at the concentrations of 10.0, 5.0,
and 1.0 μg/mL in triplicate. The accuracy was defined as the
recovery percentage, and precision was expressed as the per-
cent relative standard deviation (RSD).
Solubility Determination
CC was added, in excess, into pure solvents (water,
0.1 mol/L HCl, PBS 4.5, PBS 6.5) or to the solvents with
addition of 0.35% or 0.7% (w/w) of T20 and the resulting
suspensions were shaken for 24 h under thermostated
circumstances (310 K, i.e., 37°C) to obtain the solubility
Table I. Dissolution Media Used for Biopharmaceutical In Vitro Studies of Candesartan Cilexetil (CC) in Dosage Forms
Dosage form of CC
Dissolution medium
ReferencesRecommended Other investigated solutions
Tablets 0.35/0.7% T20 in 0.05 mol/L PBS pH 6.5 – [14]
Tablets PBS pH 7.2 PBS pH 6.5 [19]
Water
0.1 mol/L HCl
Tablets 1% SLS pH 6.8 0.1 mol/L HCl [20]
PBS pH 7.0
Fast-dissolving tablets Sorenson’s buffer pH 6.8 – [21]
Fast-dissolving tablets 0.1% T20 in PBS pH 6.8 – [22]
Nanosuspension/tablets PBS pH 6.8 0.1 mol/L HCl [10]
Acetate buffer pH 4.5
Water
Nanosuspension 0.7% T20 in 0.05 mol/L PBS pH 6.5 – [9]
Nanoemulsion 0.1 mol/L HCl – [23]
PBS pH 6.8
Artificial intestine juice (AIJ) pH 6.8
Microspheres PBS pH 6.8 – [24]
Polymeric micelles Simulated gastric fluid (SGF) pH 1.2,
after 2 h pH 7.2
– [7]
Solid lipid nanoparticles 0.1 mol/L HCl – [25]
PBS pH 6.8
SMEDDS 0.02% T20 in 0.05mol/L PBS pH 6.5 – [8, 26]
CC candesartan cilexetil, SLS sodium lauryl sulfate, PBS phosphate buffer solution, T20 polysorbate 20, SMEDDS self-microemulsifying drug
delivery system, HCL hydrochloric acid
Fig. 2. The HPLC chromatograms of candesartan cilexetyl methanolic solutions after
14 days storage at temperature 277, 298, and 310 K
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equilibrium (no further increase in dissolved drug concentration
was observed after 48 h). The amount of T20 was added
according to FDA dissolution methods [14]. To demon-
strate the effect of PBS concentration with pH 6.5 on CC
solubility, the experiment was performed in 0.01, 0.05, and
0.2 mol/L PBS (with and without T20). The samples of
saturated solutions were collected after filtration through
a 0.22 μm filter (cellulose acetate filter, Sartorius,
Goettingen, Germany) and diluted appropriately with
methanol to prevent the crystallization of the solute. The
concentrations of CC were analyzed by the HPLC
method.
Stability Study
Degradation of CC was studied in solutions prepared
with 0.1 mol/L HCl (pH 1.2), 0.05 mol/L PBS (pHs 4.5,
6.5, and 7.4), and in water (W-6.8) (pH 6.8; measured in
10 μg/ml aqueous solution of CC). Experiments were
repeated in solutions containing 0.35% or 0.7% of T20
in 0.1 mol/L HCl and PBS pH 4.5 or 6.5. The solutions
were prepared at the concentration of 10 μg/mL by dilut-
ing a 1 mg/mL methanolic stock solution; the final con-
centration of methanol in the solutions was approximately
1%. Solutions of CC in methanol were also subjected to
stability studies.
The investigated solutions were stored for 14 days in
temperature-controlled areas at 277, 298, and 310 K (4°C,
25°C, and 37°C). Aliquots were withdrawn at appropriate
time intervals and, after diluting with methanol, were imme-
diately analyzed for the remaining CC. The observed pseudo-
first-order degradation rate constants, kobs, were calculated
from the slopes of the natural-logarithmic plots of the
remaining drug fraction versus time in accordance with
Table II. The Effect of Polysorbate 20 (T20) on Solubility of
Candesartan Cilexetil (Μg/ml) in Dissolution Media at Temperature






HCl 1.0 0.23 (±47.8) 6.2 (±15.3)b 11.5 (±9.5)c
0.1 mol/L
PBS 4.5 4.5 0.51 (±37.2)a 7.8 (±12.1)b 20.1 (±8.1)c, d
0.05 mol/L
PBS 6.5 6.5
0.01 mol/L <0.05 168.8 (±2.3) 313.7 (±7.8)c, d
0.05 mol/L 0.8 (±25.8)a 192.9 (±3.9)b 353.4 (±9.4)c, d
0.2 mol/L 1.3 (32.1)a 201.5 (±5.0)b 620.3 (±6.5)d
Water 6.8 1.4 (±27.2)a 7.4 (±7.3)b 10.3 (±6.9)c
Statistically significant difference (p<0.05)
HCL hydrochloric acid, PBS phosphate buffer solution, T20 polysor-
bate 20
aCompared with HCl
bCompared with PBS 6.5 (0.01 mol/L)
cCompared with PBS 6.5 (0.2 mol/L)
dCompared with HCl
Fig. 3. Pseudo-first-order plots showing the degradation of candesartan cilexetil at temperature: a 277 K, b 298 K, and c 310 K in aqueous
solutions in the pH range 1.2–7.4 and in methanolic solution (MeOH); mean values are presented (n=5; RSD<10%)
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Eq. (1) [15]: where C0 is the initial concentration and Ct is






Coefficient of determination, r2 was used in linear
regression analysis to evaluate how the experimental data fit
the pseudo-first-order degradation kinetics.
The number of Ct measurements taken over the time span
from t0→t ranged at 5. The Arrhenius factor (A) and the activa-
tion energy (Ea) for CC degradation were determined from a
plot of ln (kobs)=f (1/T) according to Eq. (2), using the
least-squares regression: where R is the universal gas con-
stant and T is the absolute temperature (K).
lnkobs ¼ lnA− EaRT ð2Þ
RESULTS AND DISCUSSION
Validation of HPLC
Concentrations of CC in solutions were measured
using the HPLC method previously described by Lunn
[16] and modified for the purpose of this study. An ex-
ample of the chromatogram is presented in Fig. 2. The
least-squares linear regression analysis revealed the line-
arity in the concentration range of 0.2–10.0 μg/mL: the
regression line equation was y=58.076x+5.99 and the co-
efficient of determination r2 was 0.9994. The LOD was
0.05 μg/mL and the LOQ 0.17 μg/mL. The method was
characterized by the acceptable precision (≤6.0% RSD)
and accuracy (94%–104%).
Solubility
Solubilities of CC in the aqueous solvents (HCl, PBS
4.5, PBS 6.5, and W-6.8), also with an addition of 0.35%
or 0.7% of T20 at temperature 310 K are shown in
Table II (the relative standard deviations (RSD) between
the repeated determinations were not larger than 10%).
According to the pharmacopoeial classification, CC is
practically insoluble in water since its solubility was below
100 μg/ml [4]. The pH-dependent solubility profile of CC
compound was observed, however, with only slightly bet-
ter solubility at higher pH (0.23 μg/ml at pH 1.2 and
1.40 μg/ml at pH 6.8).
As determined by Satturwar et al. [7], the solubilities
of CC at temperature of 310 K in a simulated gastric fluid
with pH 1.2 (0.6 μg/ml) and in a simulated intestinal fluid
with pH 7.2 (8.6 μg/ml), although larger than reported in
the present study, are consistent with respect to pH-de-
pendent solubility. This relationship can be supported by
an acid–base equilibrium reported by Cagigal et al. [17],
who determined pKa at the value 6.3 for CC and attrib-
uted it to the deprotonation of the tetrazole group classi-
fying CC as a weak acid. The pH-dependent solubility of
CC was studied also by Nekkanti et al. [10], who conclud-
ed that the solubility decreases with an increasing pH,
however, that was not demonstrated by the experimental
results since, for micronized CC, no effect of pH was
observed and, for nonmicronized substance, the solubility
at pHs 4.5 and 6.8 was the same.
The solubility enhancement of poorly soluble drugs,
required for the dissolution studies from drug formulation,
can be achieved by using surfactants. In the present work,
the solubility of CC in water or buffers was enhanced
using T20 according to FDA recommendation (Table I).
The surfactant was used in concentrations much above the
critical micellar concentration (CMC for T20 is, according
to different literature sources, 0.001%–0.007% w/v). T20
has significantly increased the solubility of CC in all sol-
vents, with a larger effect (1.3–2.5 times larger) observed
at higher concentration, i.e., 0.7%. Since the drug is solu-
bilized in micelles, the solubility should be considered as
an apparent solubility.
At least 2.5 times lower solubility of CC (125±6.9 μg/
ml) in PBS pH 6.5 containing 0.7% of T20, than in the
present study, was reported by Detroja et al. [9], but the
experiment was performed at room temperature. Thus,
the results obtained in the present study at 310 K are
coherent.
Although solubilities of CC in PBS at pH 4.5 or 6.5
without a surfactant were comparable, but upon addition
of T20, a dramatic increase (200–500-fold) of CC solubil-
ity was observed at pH 6.5, while the effect was much
smaller at pH 4.5 (15–40-fold). The effect of T20 on CC
solubility in water (pH 6.8) was also not so spectacular. It
is interesting to note that another surfactant, namely so-
dium lauryl sulfate, added to PBS with pH 6.8 in the
concentration of 1% did not exhibit such large solubiliza-
tion effect [10].
The results suggest that micellar solubilization is more
effective in the presence of phosphate ions at higher pH. To
elucidate this phenomenon, the relationship between PBS
concentration (0.01–0.2 mol/L) and solubility of CC in the
presence of T20 was studied. It was observed (Table II) that
an increased ionic strength of PBS allows to increase drug
solubility, especially at higher concentration of T20. This effect
is not so large, however, in 0.35% of T20 solution and does not
Fig. 4. The HPLC chromatograms of candesartan cilexetil (CC)
aqueous solutions (pH 1.2–7.4) after 14 days storage at 310 K
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explain a huge difference obtained when T20 is added either
to PBS or water. Since T20 is a nonionic surfactant, one cannot
explain, without conducting further investigation, the reason
for such large solubilization effect only in PBS pH 6.5 but not
in water or in PBS pH 4.5.
Results demonstrate that at least 125 and 500 ml, respec-
tively, of 0.05 mol/L of PBS at pH 6.5 with 0.35% of T20 is
required for 8 and 32 mg tablets to achieve a minimum “sink”
conditions (approximately 30% of the saturation concentra-
tion) in dissolution studies. If T20 is used in concentration
Fig. 5. The effect of polysorbate 20 (T20 0.35 or 0.7% w/w) on degradation of candesartan cilexetil in HCl (a) and PBS buffers: pH 4.5 (b) and
pH 6.5 (c) at temperature 277, 298, and 310 K; mean values are presented (n=5; RSD<10%)
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0.7%, the volumes could be further reduced. On the other
hand, the “sink” conditions for 8 mg tablets tested in HCl or




CC in methanolic solution showed good stability with less
than 3% of the total content loss at temperature of 310 K after
14 days (Fig. 3). In an earlier report, Ferreiros et al. [11]
observed that CC degradation occurred in the methanolic
solution only upon evaporation. The formation of candesartan
and its ester was attributed to the basic hydrolysis of CC and
transesterification reaction of the pro-drug. However, CC de-
rivatives did not appear in our HPLC chromatograms when
the methanolic solutions were heated but not evaporated to
dryness.
Aqueous solutions—pH and temperature effect
The most important factors that affect the stability of
substances in solutions are pH and temperature; therefore,
the stability of CC at three different temperatures (277,
298, and 310 K ) and at five different pHs (1.2, 4.5, 6.5,
6.8, and 7.4) was investigated. Figure 3 presents the ap-
plicability of the pseudo-first-order model. The selected
model showed a linear relationship between the logarithm
of concentration Ct/C0 and the storage time (r
2 in the
range of 0.9979 to 0.8414 are presented in Table III).
This indicates that the pseudo-first-order model can be
used for predicting the kinetics of the CC degradation in
aqueous solutions. The degradation rate profiles show fast
decomposition in solution when temperature increases and
pH decreases.
In Table III, the calculated pseudo-first-order rate
constants are listed showing the effect the temperature
and pH have on the degradation rates. The pH-rate pro-
files reveal fast degradation of CC in acidic conditions.
On the basis of the Arrehnius relationship (Eq. (2)), the
linear plots of ln kobs versus 1/T were used to calculate
the energy of activation. The degradation rate of CC
increases with a decreasing pH in the following order:
PBS7.4<W (pH 6.8)<PBS6.5<PBS4.5<HCl. The lowest
energy of activation was observed for the acidic solution
(pH 1.2) and it was 29.59 kJ/mol. The change of pH from
1.2 to 7.4 results in a 1.5-fold increase of activation energy
and, depending on temperature, 8–14-fold decrease of
degradation rate (kobs).
Change of temperature from 277 to 310 K caused 4.4 to
6.6-fold increase in the rate constants, depending on the sol-
vent. After 24 h (310 K) in HCl (pH 1.2), the CC content was
at 37.0% of the initial value while in PBS7.4 was at 83.5%. The
half-lives of degradation were calculated to be from 1.5 day
(pH 1.2, 310 K) to 96 days (pH 7.4, 277 K).
Accelerated conditions result in hydrolysis and forma-
tion of candesartan in an alkaline environment and
desethyl CC in acidic and neutral conditions [12, 13, 18].
This is explained by the ionization occurring mainly above
pH 6.3 (pKa of CC). The resulting CC, in an ionized
form, is highly susceptible to hydrolysis, which leads to
the formation of candesartan, while in the nonionized
Fig. 5. (continued)
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form of CC, the ether bond between benzimidazole and
ethyl moiety is broken [11, 12, 17].
Figure 4 presents HPLC chromatograms of CC aqueous
solutions after 14 days of storage at 310 K. According to
literature data [11, 18], the peaks at retention times of 1.9
and 5.2 min were identified as a candesartan and desethyl
CC, respectively. In acidic and neutral conditions (pH ≤6.8),
an identical major degradation product was observed, repre-
sented by a peak with the retention time 5.2 min. Degradation
of CC in PBS7.4 proceeded with the formation of a major
degradation product, with a peak at the retention time of
1.9 min.
The effect of polysorbate 20
Figure 5 and Table III demonstrate the effect of micellar
solubilization of CC on its stability in an aqueous environ-
ment, dependent on pH and temperature. The protective
effect of T20 is clearly visible, similar both in acidic and
neutral solvents. The calculated energy of activation was
approximately two times higher than for the solutions
without T20, but the stability was not further increased
with the increasing concentration of T20 from 0.35% to
0.7%.
The protective effect was decreasing, however, with an
increased temperature and was only moderate or small at
310 K (relevant for a dissolution test). For example, in the
presence of T20, in acidic conditions, kobs decreased only by
28% and by 13% in pH 6.5.
Using the calculated kobs values, one can estimate the
degradation level occurring when a typical dissolution test is
performed during 1 h (nonmodified drug release formula-
tions) or during 24 h (modified dosage forms). If T20 is
used (0.35% or 0.7%) in pH 6.5, one can expect the
degradation to be at the level of 0.4% (1 h) and 9.3%
(24 h). In acidic (HCl) conditions, these values are 1.4%
and 28.3%, respectively. Thus, the dissolution test at pHs
1–6.8, required for a bio-waiver, may be performed for
conventional tablets or capsules without the danger of
degradation, but for longer tests, required for prolonged
release formulations, the acceptor fluids at pH 6.5 or
higher are suitable under the condition that the degrada-
tion is carefully monitored and the flow-through apparatus
with a nondelayed analysis is recommended.
CONCLUSIONS
CC is practically insoluble in water, and the addition
of a surfactant is required to achieve the “sink” conditions
during a dissolution test. T20, a surfactant recommended
by FDA, dramatically increases the solubility of CC in a
neutral phosphate buffer solution, while its effect at lower
pH or in water is much smaller. The effect was not
correlated, however, with the phosphate buffer concentra-
tion. The use of T20 0.35% solution in PBS at pH 6.5
enables to achieve the sink conditions in the volume of
acceptor fluid even as small as 500 ml (for 32 mg CC
doses), and this volume can be further reduced by using
0.7% of T20 solution in PBS. However, if a pH-dependent
dissolution profile is necessary, the required volume of the
acidic acceptor fluid is too large, since T20 does not
increase CC solubility in acidic conditions so dramatically.
The choice of neutral pH for dissolution studies is also
justified by the poor stability of CC in acidic conditions. T20
protects CC from degradation; this effect, however, is temper-
ature-dependent and is practically nonrelevant at 310 K.
Due to a large solubilizing effect of T20 only in PBS
solutions, despite of the insignificant effect of this surfactant
on CC stability at 310 K, we were unable to propose a more
appropriate acceptor fluid for CC dissolution studies than PBS
at pH 6.5 with T20 at the concentration of up to 0.7%, which
FDA recommends.
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